Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis

Antitumor Necrosis Factor-like Ligand 1A Therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis

Background: The first-in-class treatment PF-06480605 targets the tumor necrosis factor-like ligand 1A (TL1A) molecule in humans. Results from the phase 2a TUSCANY trial highlighted the safety and efficacy of PF-06480605 in ulcerative colitis. Preclinical and in vitro models have identified a role fo...

Full description

Bibliographic Details
Main Authors: Allegretti, J.R (Author), Baniecki, M.L (Author), Chandra, D.E (Author), Danese, S. (Author), Hassan-Zahraee, M. (Author), Hung, K.E (Author), Hyde, C.L (Author), Karlsson, F. (Author), Klopocka, M. (Author), Lepsy, C. (Author), Li, X. (Author), Longman, R. (Author), Neelakantan, S. (Author), Quan, J. (Author), Raha, N. (Author), Romatowski, J. (Author), Scherl, E.J (Author), Schoenbeck, U. (Author), Vincent, M.S (Author), Xi, L. (Author), Ye, Z. (Author), Zhang, J. (Author), Ziemek, D. (Author)
Format: Article
Language:English
Published: Oxford University Press 2022
Subjects:
Article
blood
clinical article
cohort analysis
colon tissue
drug efficacy
drug mechanism
drug targeting
endoscopy
enteritis
Haemophilus parainfluenzae
human
human cell
human tissue
inflammation
inflammatory bowel disease
intestinal fibrosis
macrophage
metagenomics
microbiome
multicenter study
nonhuman
open study
personalized medicine
pf 06480605
phase 2 clinical trial
protein inhibitor
proteomics
Streptococcus parasanguinis
Streptococcus salivarius
Th17 cell
TL1A inhibition
transcriptional response
transcriptomics
ulcerative colitis
unclassified drug
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items